Recent progress has suggested that dual targeting drug delivery systems, which are functionalized with two active ligands targeting the blood brain barrier (BBB) and brain tumor cells respectively, provide a promising strategy to improve the chemotherapeutic efficacy for gliomas. The key to successfully developing such systems is to functionalize nanoparticles (NPs) with active ligands, though they usually suffer from several issues such as NP aggregation, drug leakage and complicated chemical synthesis. Herein we report a facile way of constructing a dual targeting delivery system by simply using lipid capped polymer NPs. The NPs were constructed with a poly lactic-co-glycolic acid (PLGA) core for hydrophobic doxorubicin (DOX) loading, and a lipid (lecithin and DSPE-PEG 2000 -COOH) shell. The DSPE-PEG 2000 -COOH provides an excellent anchor for ligand conjugation. As a proof of concept, two active ligands of angiopep-2 peptide and AS1411 aptamer were covalently linked to NPs through a single step synthesis, with little effect on particle size, stability, drug loading and drug release performance. The accumulative drug release of the NPs in PBS (pH 7.4) over 144 h is $50%, suggesting a sustained drug release profile.
Introduction
Gliomas are the most frequent form of primary malignant tumor in the brain, accounting for $80% of the incidence of central nervous system tumors.
1,2 These tumors, especially highgrade gliomas and glioblastoma, grow invasively and carry a high rate of morbidity and mortality. 3, 4 Current standard treatment for gliomas is surgical resection, while it usually has poor outcomes because of the diffuse invasion of gliomas into nearby brain tissues, resulting in relapse aer treatment. 5 Due to this issue, chemotherapy presents an essential auxiliary treatment for patients with glioma aer surgery. The efficacy of chemotherapy, however, is also reported to be unsatisfactory with high side-effects. 6, 7 This can be ascribed to the non-specic bio-distribution of current therapeutic drugs and their inadequate delivery to the tumor. For brain tumors chemotherapy, a major challenge is the blood-brain barrier (BBB), which is a diffusion barrier formed by brain capillary endothelial cells (BCECs) along with other perivascular cells. This barrier is featured by the absence of fenestrations and by extensive tight junctions. This unique structure prevents nearly 100% large-molecule and more than 98% of small-molecule drugs from transporting into the brain, 8, 9 which is due to their low permeability and the high level of drug efflux by active transporters. 10 With the recent progress of nano-medicine, it has been shown that nanoparticles (NPs) functionalized with bioactive ligands is a promising tool to mediate the transportation of drugs across BBB.
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This strategy is inspired by a biological process called receptormediated transcytosis (RMT), 12 through which many nutritional bio-macromolecules are able to actively transport the BBB barrier via specic receptors, such as insulin receptor, 13 the transferrin receptor (TfR), 14 and the low-density lipoprotein receptor-related protein (LRP). 15 In principle, any ligand that is capable of binding to these receptors can facilitate the transportation of NPs into brain through this RMT process and thereby enhance the therapeutic effects. minimized, thus increasing the therapeutic index. 18 Towards this goal, the NPs need to be equipped with another targeting ligand that can promote the drug accumulation into tumor cells. Indeed, this so-called cascade dual-targeting strategy has been demonstrated to be a viable approach for glioma therapy, where the rst-stage targeting ligand circumvents the BBB barrier and the second one targets to brain cancer cells for selective drug delivery. [19] [20] [21] [22] So far, various materials and active ligands have been employed to fabricate such NPs system.
23-32
For this design, the targeting ligands are the crucial component. Based on the choice of targeting ligands, the dual targeting delivery system can be generally categorized into two types: (1) targeting BBB and tumor cells using different ligands, in which each ligand binds distinct receptor at different sites; and (2) dual targeting with one ligand, where the ligand can directly target both the BBB and brain tumor because its receptor is over-expressed on both types of cells.
The key of construction dual targeting NPs is to attach the active ligands on NPs surface. Two methods are currently available for ligands attachments. For example, the ligands can be directly conjugated to the surface of NPs. While several successful examples have been reported via this method, 28, 33, 34 a few technique challenges have been met, such as NP aggregation, drug leakage and difficulty of precisely tuning the ratio of each ligand on particle surface. Alternatively, the target ligands can be linked to the hydrophilic fragment of the polymer materials, and these modied materials were used as building block for the NPs assembly. While this method can bypass the above-mentioned issues, extensively chemical synthesis steps are usually required.
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To address this dilemma, herein we reported a general way of construction dual targeting delivery system by simply using lipid capped polymer nanoparticles, with poly lactic-co-glycolic acid (PLGA) as the core and lipids (lecithin and DSPE-PEG 2000 -COOH) as the shell. The PLGA core is able to load hydrophobic drugs with high efficiency, and the DSPE-PEG 2000 -COOH provides a carboxyl group for ligand conjugation. The most notable merit of such strategy is that the ligands can be directly conjugated to DSPE-PEG 2000 -COOH fragment before or aer NPs formulation, with a single synthesis step.
As a proof of concept, the angiopep-2 (ANG-2) was used as the rst-stage targeting ligand to facilitate the transportation of NPs into brain. ANG-2 is a peptide derived from the Kunitz domain of aprotinin, 36 which can bind LRP that expresses on the membrane of BBB. 37, 38 Because of this, it has been used to construct the BBB transportation NPs by several research groups. 23, 26, [39] [40] [41] In addition, we also utilized a second binding ligand of a DNA aptamer called AS1411 to achieve accurate glioma cells targeting. Aptamer (Apt) is a type of articial singlestranded oligonucleotide that can bind to a wide range of targets with high specicity and affinity. [42] [43] [44] AS1411 is a G-rich DNA aptamer that binds to nucleolin, a protein which is located in the nucleus and highly expressed in the plasma membrane of many cancer cells such as glioma cells. [45] [46] [47] [48] In this study, we established a cascade dual-targeting NPs platform by using lipid capped polymer nanoparticles. Both ANG-2 and aptamer AS1411 were used as binding ligands for NPs functionalization, and the doxorubicin (DOX) as a model drug to evaluate the anti-cancer effect. The resulting dual targeting nanoparticles showed receptors-mediated cellular uptake, signicantly enhanced BBB penetration and antiproliferation effect in vitro. This work provides a facile way of construction dual targeting delivery system for chemotherapy of gliomas. 
Materials and methods

Materials
Carboxyl
Preparation of NPs
The DOX free base was obtained by reacting DOX hydrochlorate with 3 molar equivalents of triethylamine (TEA) in 12.5% (v/v) methanol in chloroform solution overnight. 49 The DOX-loaded NPs were prepared by the emulsion/solvent evaporation method. 45, 50 In a typical procedure, 20 mg of PLGA and 1 mg of DOX were dissolved in 2 mL of 12.5% (v/v) methanol in chloroform solution. The resultant organic solution was emulsied in 6 mL of aqueous solution containing 1% PVA (w/v), 2.1 mg soybean lecithin and 0.9 mg DSPE-PEG 2000 -COOH to form an oil-in-water emulsion by sonication (120 W) for 2 min on ice bath using probe sonication (Branson, USA). The emulsion was stirred overnight at room temperature on a magnetic stir plate to allow evaporation of the organic solvent and the formation of NPs. NPs were centrifuged at 20 000 rpm for 20 min at 4 C (TGL 20M, Hunan, China), and washed 3 times with deionized water to remove unbound PVA and free DOX. Then, the NPs were re-dispersed in deionized water for further use.
The conjugation of ANG-2 and Apt to the surface of NPs were performed by pre-functionalization strategy using an EDC/NHS technique. Briey, the carboxyl unit of DSPE-PEG 2000 -COOH was activated by EDC and NHS for 0.5 h and then reacted with amino-modied ANG-2 or AS1411 (the molar ratio of DSPE-PEG 2000 -COOH to ANG-2 or AS1411 was 1 : 1) in 1 mL of PBS (pH 7.4) for 4 h in the dark. The conjugates were transferred into an ultraltration tube (MWCO is 10 kD and 5 kD for AS1411 and ANG-2 conjugation, respectively) and centrifuged at 3000 rpm for 20 min, and then washed with deionized water until there was no absorption in the ltrate to obtain pure DSPE-PEG 2000 -ANG-2 and DSPE-PEG 2000 -Apt. AS1411 modied NPs (Apt-NPs/DOX) and ANG-2 modied NPs (ANG-NPs/DOX) were prepared with the same emulsion/solvent evaporation method as described above using the respectively modied DSPE-PEG 2000 . To prepare ANG-2 and AS1411 dualfunctionalized NPs (AA-NPs/DOX) a mixture of DSPE-PEG 2000 -ANG-2 and DSPE-PEG 2000 -Apt (at 1 : 1 ratio) were used.
Characterization of NPs
2.4.1 Determination of particle size, zeta potential and morphology. Particle size, polydispersity index (PDI) and zeta potential of the NPs were determined by dynamic light scattering (DLS) analysis using zetasizer (Nano-ZS, Malvern Instruments, UK) at 25 C. The morphology of the NPs was characterized by using transmission electron microscopy (TEM, Titan G2 60-300, FEI, USA).
Evaluation of the drug loading (DL) and drug encapsulation efficiency (EE).
To determine the DL and EE, the NPs were diluted in methanol for ultrasonication to release DOX. The content of DOX was determined by HPLC measurement following a previously reported protocol. 50 The DL and EE of DOX in the NPs were calculated as follows: DL (%) ¼ amount of loaded DOX in the NPs/ weight of NPs Â 100 EE (%) ¼ amount of loaded DOX in the NPs/ total amount of DOX added Â 100
2.4.3
In vitro release studies. The in vitro release behaviors of DOX from NPs were investigated by a dialysis method. Briey, 1 mL of AA-NPs/DOX, ANG-NPs/DOX, Apt-NPs/DOX, NPs/DOX or free DOX solution was transferred into a dialysis bag (MWCO: 3500). The dialysis bag was end-sealed and submerged into 20 mL dissolution medium (PBS, pH 7.4) which was placed in a thermostatic shaker and shaken horizontally at 100 rpm at 37 C. At predetermined time points (0. twice with PBS, the uorescent distribution of cells was visualized with an inverted uorescence microscope (Ti-S, Nikon, Japan). 2.5.2 Quantitative cellular uptake studies. BCECs and C6 glioma cells were incubated in 6-well plates with 2 mL per well at a density of 2 Â 10 5 cells per mL for 24 h. Then the medium was removed and cells were washed twice with PBS, and 2 mL each formulation in FBS-free DMEM with a nal concentration of 50 mg mL À1 of DOX was added to each well and incubated for 1 h, respectively. Then the cells were washed 3 times with ice cold PBS to remove unbound particles, trypsinized with 500 mL of trypsin solution and harvested by centrifuged at 1000 rpm for 5 min. Aer resuspended in 0.5 mL of PBS, the cellular uptake of NPs was investigated by ow cytometry (FACSVerse, BD, USA).
Construction of in vitro BBB model and transendothelial transport experiments
The in vitro BBB model was established by using the co-culture of BCECs and astrocyte cells as previously described. 
At the beginning of the transport experiments, the medium in the donor chamber was replaced with 1.5 mL of FBS-free DMEM containing AA-NPs/DOX, ANG-NPs/DOX, Apt-NPs/ DOX, NPs/DOX or free DOX at a concentration of 50 mg mL À1 of DOX. Then cells were incubated on a platform, shaking at 50 rpm at 37 C. At 1, 6, 12, and 24 h, 400 mL of sample medium was taken from the acceptor chamber and an equal volume of FBS-free DMEM was added to the acceptor chamber for compensation. The samples were freeze dried and the total amount of DOX was analyzed by HPLC aer methanol treatment to release DOX in NPs.
In vitro cytotoxicity assay
In vitro cytotoxicity of NPs and free DOX against C6 glioma cells were evaluated by the MTT assay. Cells were seeded at a density of 5 Â 10 4 cells per mL in a 96-well plate and incubated for 24 h. ) was added followed by incubation for another 4 h. Then, the supernatant of each well was removed and 100 mL of DMSO was added to dissolve the metabolized product MTT formazan. Finally, the plate was shaken for 10 minutes, and optical density (OD) of the formazan product was measured by a microplate reader (Innite M200, Tecan, Switzerland) at 570 nm. The cell viability and the halfmaximal inhibitory concentration (IC 50 ) were calculated.
Statistical analysis
Analysis was performed using SPSS19.0 soware. One-way ANOVA analysis of variance was used to determine the statistical signicance of differences among groups. P < 0.05 was considered statistically signicant in all cases. Fig. 1A showed the scheme of the preparation and structure of our drug delivery system. The nanoparticles contain a biocompatible and biodegradable PLGA core for DOX loading. It is known that PLGA core could signicantly enhance hydrophobic drugs encapsulation and retard their diffusion, leading to high drug loading efficiency and sustained drug release. 52 The particle surface was sealed by a polyethylene glycol (PEG) functionalized lipid monolayer, which mainly serves two roles: rst, the PEG chain not only provides steric hindrance to increase colloidal stability of NPs and reduce protein adsorption, [53] [54] [55] but also protects the internal PLGA from directly contacting with water thus impeding hydrolysis; in addition, the terminal carboxyl group PEG offers an anchor for further conjugation of Apt and ANG-2.
Results and discussion
Preparation and characterizations of AA-NPs/DOX
The nanoparticles were prepared using a standard emulsion/ solvent evaporation method as we described previously.
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Briey, the hydrophobic PLGA and DOX were dissolved in organic phase of methanol/chloroform, and then added to the aqueous phase of lipids solution in a dropwise manner. Since PLGA is insoluble in water, it self-assembled into NPs for DOX encapsulation, and the particle surface was capped with the lipids. To conjugate the active ligands on the surface of NPs, two different methods can be used. We rst try to directly attach the ligands on above prepared NPs. However, this method resulted in poor NP stability during the reaction, which is likely due to the compromised lipid layer integrity during the conjugation. In addition, we observed signicant particle size increase and drug leakage aer ligand functionalization (data not shown). We therefore referred to the pre-conjugation method as shown in Fig. 1A , where the ligands were conjugated to the free lipid rst prior to the NPs preparation. The conjugate efficiency for both Apt and ANG-2 were determined to be $50% (Fig. S1 and S2 †) . Aer purication, these functionalized lipids can be used individually to prepare single targeting Apt-NPs (with AS1411) and ANG-NPs (with ANG-2) respectively, or a combination of these two lipids resulted in dual targeting NPs of AA-NPs.
The as-prepared AA-NPs were semi-transparent with red opalescence (Fig. 1A) , and the color is attributable to DOX loading. The particle size of NPs, Apt-NPs, ANG-NPs and AANPs were approximately 160 nm with a narrow distribution (PDI < 0.1) (Table 1) , and a representative measurement of AA-NPs was shown in Fig. 1B . The zeta potential of the NPs was approximately À12 mV. It is known that, to rely on the electric charge for NPs stabilization, the zeta potential needs to be kept >25 mV (positive or negative). Therefore, the major force to stabilize the NPs is likely due to the steric hinderance derived from PEG, rather than electrostatic repulsion. Note that the Apt and ANG conjugation have little effect on particle size and zeta potential. It is reasonable as the DSPE-PEG 2000 -COOH component accounts only for a small fraction of nanoparticle structure ($4% by mass), and the negative charge is mainly originated from the terminal carboxyl group on PLGA. 57 Thus, the colloidal stability of NPs was not affected by active ligands functionalization. The EE and DL were also unaffected by the ligands conjugation to remain at $44% and $1.7% respectively, which is reasonable as the drug was mainly loaded at the PLGA core. The particle morphology of AA-NPs was further determined by transmission electron micrographs (TEM), indicating the NPs spherical with homogenous size (inset of Fig. 1B) . We notice that the particle size measured by TEM was slightly smaller ($100 nm) than that of DLS detection, which is due to the particle dehydration before TEM measurement. The 1 H-NMR was used to conrm that the ligands functionalized DSPE-PEG 2000 -COOH was attached to the surface of NPs (Fig. 1C) . Compared with PLGA NPs (NPs prepared without the addition of DSPE-PEG 2000 -ANG/Apt), AA-NPs showed a characteristic peak at 3.5 ppm, which is attributed to the methylene protons in DSPE-PEG 2000 -ANG/Apt. Therefore, the DSPE-PEG 2000 -ANG/Apt fragment was successful inserted into the NPs structure and the dual targeting delivery system was developed.
In vitro drug release of DOX from different NPs was carried out in the medium of phosphate buffer solution (PBS, pH 7.4) to simulate the physiological environment. Over 80% of the free DOX diffusively cross the dialysis membrane aer 4 h, and the process was completed within 8 h (>95% release) (Fig. 2, black  trace) . By contrast, aer encapsulation into nanoparticles, a remarkable sustained drug release was observed. The drug release performance of different nanoparticle formations was almost identical (Fig. 2) , which can be explained by that the modications occurred at the particle surface, while DOX was mainly trapped in the PLGA core. An initial drug release from NPs was observed in the rst 24 h ($40%), followed by a much slower rate thereaer. The cumulative drug release aer 140 h was about 50% for different NPs. This drug release performance follows a typical prole of polymer-based NPs, 58 suggesting the successful encapsulation of DOX in PLGA NPs core. This sustained drug release property allows for decreased administrating frequency and thus enhances the patient compliance.
Cell uptake studies
So far, we have constructed nanoparticles with surface dual functionalized with ANG-2 and AS1411 using a simple yet controllable method. The cell uptake experiments were then designed to evaluate the targeting efficiency of these active ligands through uorescent microscopy and ow cytometry in vitro. It has been reported that BCECs have a relatively high level of LRP expression on cell surface, 38, 59 and ANG-2 can specically bind to LRP for transcytosis of the brain delivery.
15,36 Therefore, BCECs was used as a model to study the targeting ability of ANG-2 on nanoparticle surface (Fig. 3A) .
To localize cells, cell nuclei were stained blue by DAPI (Fig. 3A, lane 1) . The NPs were internalized by endocytosis, and were expected to be collapsed and digested by endosomes and lysosomes to release DOX. Therefore, the relative extent of cell uptake of NPs can be indicated by the intrinsic red uorescence of DOX. The red uorescence was observed in the cytoplasm for all test groups (Fig. 3A, lane 2) , signifying the successful internalization of the NPs, otherwise the uorescence would be observed mostly on the contour of the cells. Specically, aer incubating with unmodied NPs, only moderate red uores-cence was observed inside cells. A similar uptake was observed for Apt modied NPs. With ANG-2 modication, on the other hand, the ANG-NPs/DOX exhibited obviously stronger red uorescence signal inside BCECs cells, suggesting the role of ANG-2 in assisting cellular uptake. This result was consistent with previous work that the surface ANG-2 conjugation could enhance cell uptake in intro via LRP-mediated endocytosis.
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For the dual modied NPs (i.e. AA-NPs), we also observed signicantly brighter red uorescence compared with ANG-2 lacking NPs. Therefore, the presence of Apt on NPs surface does not hamper the target binding ability of ANG-2. It should be noted that the AA-NPs was constructed using a mixture of DSPE-PEG 2000 -ANG-2 and DSPE-PEG 2000 -Apt at 1 : 1 molar ratio. Therefore, the surface density of ANG-2 on AA-NPs was only half that of ANG-NPs, while their cell uptake efficiencies were comparable. We rationalized this by that the amount of ANG-2 on AA-NPs is already saturate for cell binding, and aer that no further enhancement can be achieved by increasing ANG-2 density. Indeed, similar phenomenon was also observed in our previous work by using another binding ligand for tumor targeting delivery. 50 To have a better comparison, we merged the uorescence of DAPI and DOX channels for different groups, and the results were presented in the third lane of Fig. 3A . It is clearly showed that ANG-2 modied NPs (i.e. AA-NP and ANGNPs) have relatively higher uptake in each cell compared with ANG-2 free NPs (i.e. Apt-NPs and NPs).
Quantitative results were obtained from ow cytometry (Fig. 3B and C) . In consistent with the above observations, the NPs decorated with ANG-2 displayed uorescence signicantly stronger than those treated with unmodied NPs ($1.7-fold higher). In addition, Apt and ANG-2 dual decorated NPs (AANPs) also showed higher uorescence, as the case of ANG-NPs.
The target efficiency of AS1411 functionalized NPs was similarly studied by using nucleolin over-expressed C6 glioma cells (Fig. 4A) . 60 In this case, the Apt modied NPs (i.e., AA-NPs and Apt-NPs) displayed higher level of red uorescence than those of Apt lacking NPs inside cells, demonstrating that the cellular association of NPs was facilitated by the specic interaction between AS1411 and nucleolin. We also quantied the relative cell uptake by using ow cytometry (Fig. 4B and C) . Based on the quantication result, ANG-2 modied NPs also showed a marginally increased uorescence compared with unmodied NPs (1.5-fold higher). This is because LRP1 is also expressed on glioma cells. 15, 37 Therefore, ANG-2 modication also gives rise to enhanced NPs uptake by glioma cells. Because of its dual targeting ability (both to BBB and glioma cells), ANG-2 has been widely employed as ligand in brain tumor drug delivery. 33, 34, 61 With Apt decoration, the Apt-NPs displayed even stronger intensity in C6 glioma cells, with 2.4-fold higher than that of unmodied NPs. Therefore, compared with ANG-2, AS1411 has better binding affinity to glioma cells. Interestingly, dual modifying NPs with ANG-2 and AS1411 further enhances the uorescence slightly, suggesting a synergistic effect of these two ligands for interacting with C6 glioma cells. Collectively, the dual targeting property of the AA-NPs has been demonstrated for both BCECs and C6 glioma cells.
In vitro evaluation of BBB penetration
Having demonstrated the dual targeting efficiency of the AA-NP/DOX, we next studied in vitro BBB penetration ability. BCECs and astrocyte cells were chosen to construct the in vitro BBB model in this study. The permeability of the co-culture model was monitored by transepithelial electrical resistance (TEER), which reects the structural integrity of the in vitro BBB model. We measured the TEER as a function of time aer BCECs seeding. The TEER value gradually increased over time until reaching a plateau of $260 U cm 2 ( Fig. 5A) , indicating a successful construction of in vitro BBB model. Once the TEER value was constant, different NPs formulations were added to the interior of the Transwell chamber and the transportation of total DOX was measured by HPLC aer culturing various hours at 37 C and 5% CO 2 .
The transport percentage of DOX across the BBB model over a period of 24 h were shown in Fig. 5B . For all groups, the amount of DOX transportation was in a time-dependent fashion. Longer incubation time results in higher amount of DOX transportation. Aer 24 h incubation, the transport percentages were calculated to be 14.6%, 15.5%, 6.3%, 5.8% and 3.6% for AA-NPs, ANG-NPs, Apt-NPs, and free DOX, respectively. The transportation of free DOX is the lowest, which is because it is passively diffused into BBB cells and can be easily effluxed by active transporters. 10 Aer formulation of NPs, the accumulative delivery of DOX is moderately higher, which is likely due to the endocytosis mechanism of NPs by cells. Notably, with ANG-2 modication on NPs surface, we observed remarkably stronger transportation, which is $2.7-and 4.3-fold higher than that of ANG-2 lacking NPs and free DOX, respectively. This result is consistent with the above cell update study, showing that the transport of DOX across the BBB model was signicantly increased by ANG-2 modication. In addition, the AA-NPs achieved a comparable DOX transportation efficiency to that of ANG-NPs, further conrming the largely retained functionality of ANG together with AS1411 modication.
In vitro cytotoxicity assay
Finally, the in vitro cytotoxicity of free DOX and different DOX loaded NPs were studied by MTT assay with C6 glioma cells (Fig. 6) . In general, the cytotoxicity progressively increased with higher DOX concentration aer 48 h incubation, based on which the IC 50 values of each test group were calculated. The IC 50 values of AA-NPs, ANG-NPs, Apt-NPs, NPs and free DOX were 0.91, 3.26, 0.78, 6.18, 1.37 mM, respectively. Note that, free DOX showed even stronger inhibitory effect than non-Apt modied NPs, with IC 50 value 4.5-and 2.4-fold lower than those of NPs and ANG-NPs, respectively. Indeed, this result was consistent with previous reports. 62, 63 We rationalized this phenomenon by that free DOX could rapidly diffuse into cancer cells to exert its cytotoxic function, while NPs need a time-consuming step to release DOX for activity. However, aer Apt modication, the cytostatic activity of NPs was strongly enhanced. For example, the Apt-NPs and AA-NPs achieved IC 50 1.76-and 1.5-fold lower than that of free DOX, respectively. This improved cytotoxicity can be ascribed to the specic interaction between AS1411 aptamer and nucleolin C6 glioma cell membrane, which tremendously enhances the cell uptake of the NPs (P < 0.05).
Conclusion
In summary, we have developed a robust strategy to construct dual targeting NPs for anti-glioma therapy. Two active ligands of ANG-2 and AS1411 Apt were successfully conjugated to NPs surface through a simple chemical technique with high efficiency and little perturbation on NPs quality. Compared with the unmodied NPs, AA-NPs exhibited signicantly higher cellular uptake in both BCECs and C6 glioma cells, improved ability to penetrate the BBB, and better inhibitory effect toward C6 glioma cells. All these results indicated that such lipid capped polymer NPs with active ligands functionalization are promising anticancer drug delivery system for glioma treatment.
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